Last week, Brazil obtained marketing authorization for Tafamidis for ATTR cardiomyopathy (ATTR-CM)

The refund approval process will begin now.

It is important to note that in the past two months, Brazil has experienced 2 other important events.

The marketing authorization for Inotersen for ATTR PN has been published and the reimbursement approval process has been launched

The Patisiran marketing authorization request dossier for hATTR PN has been submitted

There is no doubt that 2020 will be a great year for ATTR patients in Brazil!